Katherine J Bangen1,2, Kelsey R Thomas1,2, Alexandra J Weigand1,2,3, Emily C Edmonds1,2, Alexandra L Clark1,2, Seraphina Solders4, Lisa Delano-Wood1,5, Douglas R Galasko4, Mark W Bondi2,5. 1. Research Service, VA San Diego Healthcare System, San Diego, California, USA. 2. Department of Psychiatry, University of California, San Diego, La Jolla, California, USA. 3. San Diego State University/University of California, San Diego Joint Doctoral Program in Clinical Psychology, San Diego, California, USA. 4. Department of Neuroscience, University of California, San Diego, La Jolla, California, USA. 5. Psychology Service, VA San Diego Healthcare System, San Diego, California, USA.
Abstract
INTRODUCTION: Neurofilament light (NFL) reflects neuroaxonal damage and is implicated in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Little is known about NFL in pre-MCI stages, such as in individuals with objectively-defined subtle cognitive decline (Obj-SCD). METHODS: Two hundred ninety-four participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent baseline blood draw and serial neuropsychological testing over 5 years of follow-up. RESULTS: Individuals with Obj-SCD and MCI showed elevated baseline plasma NFL relative to the cognitively normal (CN) group. Across the sample, elevated NFL predicted faster rate of cognitive and functional decline. Within the Obj-SCD and MCI groups, higher NFL levels predicted faster rate of decline in memory and preclinical AD composite score compared to the CN group. DISCUSSION: Findings demonstrate the utility of plasma NFL as a biomarker of early AD-related changes, and provide support for the use of Obj-SCD criteria in clinical research to better capture subtle cognitive changes.
INTRODUCTION: Neurofilament light (NFL) reflects neuroaxonal damage and is implicated in mild cognitive impairment (MCI) and Alzheimer's disease (AD). Little is known about NFL in pre-MCI stages, such as in individuals with objectively-defined subtle cognitive decline (Obj-SCD). METHODS: Two hundred ninety-four participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) underwent baseline blood draw and serial neuropsychological testing over 5 years of follow-up. RESULTS: Individuals with Obj-SCD and MCI showed elevated baseline plasma NFL relative to the cognitively normal (CN) group. Across the sample, elevated NFL predicted faster rate of cognitive and functional decline. Within the Obj-SCD and MCI groups, higher NFL levels predicted faster rate of decline in memory and preclinical AD composite score compared to the CN group. DISCUSSION: Findings demonstrate the utility of plasma NFL as a biomarker of early AD-related changes, and provide support for the use of Obj-SCD criteria in clinical research to better capture subtle cognitive changes.
Authors: Paul K Crane; Adam Carle; Laura E Gibbons; Philip Insel; R Scott Mackin; Alden Gross; Richard N Jones; Shubhabrata Mukherjee; S McKay Curtis; Danielle Harvey; Michael Weiner; Dan Mungas Journal: Brain Imaging Behav Date: 2012-12 Impact factor: 3.978
Authors: Laura E Gibbons; Adam C Carle; R Scott Mackin; Danielle Harvey; Shubhabrata Mukherjee; Philip Insel; S McKay Curtis; Dan Mungas; Paul K Crane Journal: Brain Imaging Behav Date: 2012-12 Impact factor: 3.978
Authors: Edmond Teng; Brian W Becker; Ellen Woo; David S Knopman; Jeffrey L Cummings; Po H Lu Journal: Alzheimer Dis Assoc Disord Date: 2010 Oct-Dec Impact factor: 2.703
Authors: Suzanne E Schindler; Julia D Gray; Brian A Gordon; Chengjie Xiong; Richard Batrla-Utermann; Marian Quan; Simone Wahl; Tammie L S Benzinger; David M Holtzman; John C Morris; Anne M Fagan Journal: Alzheimers Dement Date: 2018-03-02 Impact factor: 21.566
Authors: Katie E Osborn; Jonathan M Alverio; Logan Dumitrescu; Kimberly R Pechman; Katherine A Gifford; Timothy J Hohman; Kaj Blennow; Henrik Zetterberg; Angela L Jefferson Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Stephanie A Schultz; Jeremy F Strain; Adedamola Adedokun; Qing Wang; Oliver Preische; Jens Kuhle; Shaney Flores; Sarah Keefe; Aylin Dincer; Beau M Ances; Sarah B Berman; Adam M Brickman; David M Cash; Jasmeer Chhatwal; Carlos Cruchaga; Michael Ewers; Nick N Fox; Bernardino Ghetti; Alison Goate; Neill R Graff-Radford; Jason J Hassenstab; Russ Hornbeck; Clifford Jack; Keith Johnson; Nelly Joseph-Mathurin; Celeste M Karch; Robert A Koeppe; Athene K W Lee; Johannes Levin; Colin Masters; Eric McDade; Richard J Perrin; Christopher C Rowe; Stephen Salloway; Andrew J Saykin; Reisa Sperling; Yi Su; Victor L Villemagne; Jonathan Vöglein; Michael Weiner; Chengjie Xiong; Anne M Fagan; John C Morris; Randall J Bateman; Tammie L S Benzinger; Mathias Jucker; Brian A Gordon Journal: Neurobiol Dis Date: 2020-06-06 Impact factor: 5.996
Authors: Michael Khalil; Lukas Pirpamer; Edith Hofer; Margarete M Voortman; Christian Barro; David Leppert; Pascal Benkert; Stefan Ropele; Christian Enzinger; Franz Fazekas; Reinhold Schmidt; Jens Kuhle Journal: Nat Commun Date: 2020-02-10 Impact factor: 14.919
Authors: Denis S Smirnov; Nicholas J Ashton; Kaj Blennow; Henrik Zetterberg; Joel Simrén; Juan Lantero-Rodriguez; Thomas K Karikari; Annie Hiniker; Robert A Rissman; David P Salmon; Douglas Galasko Journal: Acta Neuropathol Date: 2022-02-23 Impact factor: 15.887